Mining Stakeholder Insights On Access To Gene Therapies For Hemophilia

Situation:

• High cost of hemophilia treatment is a significant cost driver for many employers, despite relatively low disease prevalence
• Precision’s client sought to understand how a paradigm shift to a onetime gene therapy may impact employers

Learn how we were able to develop strategic recommendations on opportunities to engage employer groups, coalitions, and benefit consultants through gene therapy education and collaborative partnerships to promote buy-in of this stakeholder as new gene therapy comes to market